effect on the upregulation of these cell surface markers. The mean peak fluorescence intensity

Transcription

1 SUPPLEMENTARY FIGURE 1 Supplementary Figure 1 ASIC1 disruption or blockade does not effect in vitro and in vivo antigen-presenting cell activation. (a) Flow cytometric analysis of cell surface molecules (CD40, CD80, CD86 and I-Ak (MHC class II)) on untreated or amiloride-treated EOC20 microglia cells after 48 h incubation with LPS or IFN-γ. Amiloride (100 µm) showed no effect on the upregulation of these cell surface markers. The mean peak fluorescence intensity is given in the respective histograms and represents one of two separate experiments. (b) Draining lymph nodes (n = 3 per group) from untreated or amiloride-treated (from day 5 p.i.) MOG35 55 immunized WT or untreated Asic1 / mice were isolated at day 10 p.i. and analyzed by flow cytometry. Activation markers CD40, CD80, CD86 and MHC class II (IA/I-E) expression were analyzed on CD11b+CD11c+ dendritic cells (gated population is indicated in flow cytometry plot). No significant differences could be detected in the mean fluorescent intensities of stained cells. Representative histogram overlays are shown and values represent mean fluorescent intensities.

2 SUPPLEMENTARY FIGURE 2 Supplementary Figure 2 Schematic demonstration of the mechanism of action for ASIC1 in axonal degeneration. (1) T cell activation and proliferation increase the population of autoreactive T cells within the CNS and drive the inflammatory response. (2) Autoimmune CNS inflammation then initiates a cascade with subsequent release of toxic mediators, including nitric oxide and oxygen free radicals. (3) Energy failure ensues due to nitric oxide induced mitochondrial dysfunction causing (4) tissue acidosis. The increased concentration of protons (acidosis) leads to activation of ASIC1 expressed along axons, dendrites or neuronal cell bodies. (5) Opening of ASIC1 leads to influx and accumulation of injurious Na + and Ca 2+ ions. Activation of secondary injury cascades, such as proteases, causes breakdown of the axonal cytoskeleton leading to (6) axonal degeneration and development of non-remitting clinical deficits. (7) Pharmacological blockade of ASIC by amiloride and other related compounds acts through neuroprotective mechanisms with potential for amelioration of CNS inflammatory disease.

3 SUPPLEMENTARY METHODS Flow cytometry. Antibodies used for flow cytometry analysis were directed against CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), CD11c (HL3), NK1.1 (PK136), CD40 (3/23), CD80 (16-10A1), CD86 (GL1), I-A k (10-3.6), I-A/I-E (M5/ ) (all from Becton Dickenson) and CD19 (6D5; Serotec). Analysis was done by using a Cyan ADP (Dako). Tissue analysis. For analysis of sections, multiple representative images were accrued with a confocal microscope (Radiance 2000; Bio-Rad Laboratories) system on a microscope (BX51; Olympus). Two to four blinded images per animal were taken of the dorsal corticospinal tract (n = 5 per group, 121,105 total axons), dorsal column (n = 5 per group, 22,467 total axons) and optic nerve (n = 5 per group in vivo, 71,071 total axons; n = 4 5 per group in vitro, 232,187 total axons) through a 100x objective (UplanF1; Olympus), with a 2x digital zoom using Lasersharp software (Bio-Rad Laboratories). Quantification of axonal profiles was performed utilizing ImageJ and adapted ICTN plugin which counted axonal profiles based on a minimum diameter of the axon, separation and threshold intensity with values fixed across experimental groups for each type of tissue examined. Accuracy of automated counting technique was confirmed by manual counting of sample images (2,400 axons approx.) with <2% non significant difference (P = 0.89) in the number of axons between a blinded observer and automated counting technique. Moreover, estimates of the total numbers of axons in WT controls of optic nerve (42,000 per optic nerve) and corticospinal tract (25,000 per unilateral dorsal corticospinal tract) by ImageJ/ICTN is consistent with previous studies 1,2. To examine the effect of Asic1 / or amiloride treatment on the inflammatory cell population in EAE, a pre-designed grid (consisting of four quadrants each 71 µm x 284 µm) was superimposed on images orientated superficially to deep and the number of CD45 + CD3 or CD45 + CD3 + cells 1

4 counted. To insure random sampling, two quadrants (one each from dorsal and ventral portions of the cord) were selected from each of four images per animal (both quadrants and images were randomly selected) and analyzed. Data are expressed as the mean number of CD45 + CD3 or CD45 + CD3 + cells per 4 x 10 4 µm 2 per animal in WT controls, WT-EAE, Asic1 / -EAE and amiloride-treated WT-EAE mice. Analysis of HIF-1α immunostaining was determined by measuring the mean pixel intensity of HIF-1α in spinal cord tissue from the dorsal spinal column from both EAE and control images (n = 4 5 per group). Background optical intensity was subtracted from all images under identical conditions and data is presented as mean ± s.e.m.. For analysis of in situ hybridization semi-quantitative microdensitometry was utilized. Images were captured using an Olympus BX60 light microscope with a 40x objective. Digitally captured images were converted to grayscale using ImageJ processing software. The same software was utilized to quantify the optical intensity of in situ hybridization signals in retinal ganglion cell and Purkinje cell neurons, which were manually outlined. Background optical intensity was subtracted from all signals under identical conditions for both EAE and control images (n = 3 4 per group). EOC20 microglial cells Microglia EOC20 cells, derived from C3H/HeJ CH-2k mice (ATCC) 3 were grown as recommended using DMEM media supplemented with 1 mm sodium pyruvate, 10% FCS and 20% LADMAC (ATCC) conditioned media. EOC20 cells were stimulated in the absence or presence of 100 µm amiloride with LPS (200 ng/ml) or interferon-γ (200 U/ml) for 48 h, stained for the respective surface markers and analyzed by flow cytometry, gated on living cells by using BD Viaprobe (Becton Dickinson). 2

5 SUPPLEMENTARY REFERENCES 1. Hsu, J.Y., Stein, S.A. & Xu, X.M. Development of the corticospinal tract in the mouse spinal cord: a quantitative ultrastructural analysis. Brain Res 1084, (2006). 2. Jeon, C.J., Strettoi, E. & Masland, R.H. The major cell populations of the mouse retina. J Neurosci 18, (1998). 3. Walker, W.S., Gatewood, J., Olivas, E., Askew, D. & Havenith, C.E. Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigenpresenting activities for naive and memory CD4+ and CD8+ T cells. J Neuroimmunol 63, (1995). 3

6 Supplementary Table 1. Clinical characteristics of MOG35 55-induced EAE Mouse genotype Treatment Incidence Day of disease onset a Maximum clinical score a Clinical score at day 30 p.i. a WT-EAE PBS from day 5 p.i. or none 52/59 (88%) 9.65 ± ± ± 0.89 Asic1 +/ -EAE None 6/6 (100%) 9 ± ± ± 0.71 Asic1 / -EAE None 22/25 (88%) 9.35 ± ± 1.13 (P = ) b 1.81 ± 1.07 (P = ) b Amiloride from 38/ ± ± ± 0.74 WT-EAE day 5 p.i. (86%) (P = 0.031) b (P = 5 x 10-6 ) b (P = 2 x ) b a Results are presented as mean ± s.d. and represent pooled data of at least three independent experiments. b P values refer to an ANOVA test in comparison with WT-EAE.

7 Supplementary Table 2. Axonal protection within an optic nerve injury model in Asic1 / mice or by blockade of ASIC in vitro Total axons/3,250 µm 2 (SMI 31 and 32) a Injured axons/3,250 µm 2 (SMI 32) a control ph 6.5 control ph 6.5 WT 1,463 ± 55.7 Asic1 / 1,457 ± ± ± 7.9 (P = 0.002) b 1,148 ± ± 7.4 (P = 0.006) c 366 ± 71.3 (P = 0.009) b 34.6 ± 3.3 (P = 0.01) c WT + PcTx1 n.a. 1,036 ± 61.5 n.a. (P = 0.01) c 81.5 ± 21.6 (P = 0.01) c WT + amiloride n.a. 1,138 ± n.a. (P = 0.04) c 162 ± 34.9 (P = 0.04) c a Results are presented as mean ± s.e.m of 4 5 optic nerves per group b Compared to WT control c Compared to WT control at ph 6.5 n.a., not applicable

8 Supplementary Table 3. Axonal degeneration and inflammatory reaction in MOG induced EAE Number of neurofilament (SMI 31 and 32) positive axons/3,250 µm 2 Number of CD45 + CD3 cells/4,000 µm 2 spinal cord (dorsal and ventral columns) Number of CD45 + CD3 + cells/4,000 µm 2 spinal cord (dorsal and ventral columns) Corticospinal tract a Dorsal column a Optic nerve a Day 15 post immunization a Day 15 post immunization a WT 2,395 ± ± 7.4 1,443 ± ± ± 0.1 Asic1 / 2,523 ± ± ,409 ± 38.3 n.d. n.d. 1,198 ± ± ± ± ± 3.0 WT-EAE (P = 4 x 10-6 ) b (P = 5 x 10-6 ) b (P = ) b (P = ) b (P = 0.002) b 2,139 ± ± ,424 ± ± ± 2.7 Asic1 / -EAE (P = ) c (P = 0.007) c (P = 0.002) c (P = 0.07) c (P = 0.8) c WT-EAE + amiloride 2,003 ± (P = 0.001) c 294 ± 26.3 (P = 0.02) c 1,339 ± 37.9 (P = 0.002) c n.d. n.d. a Results are presented as mean ± s.e.m of 4 6 animals per group. b Data compared to WT c Data compared to WT-EAE n.d., not determined

9 Supplementary Table 4. Subset analysis in WT and Asic1 / mice Organ Markers Cell type WT (%) a Asic1 / (%) a CD3 + CD4 + CD4 + T cells 22.2 ± ± 0.7 CD3 + CD8 + CD8 + T cells 15.0 ± ± 0.4 CD3 + NK1.1 + NKT cells 4.4 ± ± 0.4 Spleen CD3 NK1.1 + NK cells 5.3 ± ± 1.3 CD19 + B cells 59.2 ± ± 10.5 CD11b + CD11c + DCs 8.4 ± ± 3.4 CD11b + CD11c Macrophages 10.1 ± ± 2.8 CD3 + CD4 + CD4 + T cells 33.0 ± ± 7.6 CD3 + CD8 + CD8 + T cells 23.1 ± ± 6.0 CD3 + NK1.1 + NKT cells 1.7 ± ± 0.9 Lymphnode CD3 NK1.1 + NK cells 1.0 ± ± 0.2 CD19 + B cells 32.8 ± ± 12.4 CD11b + CD11c + DCs 2.8 ± ± 1.9 CD11b + CD11c Macrophages 7.2 ± ± 3.0 CD3 + CD4 + CD4 + T cells 3.3 ± ± 0.4 CD3 + CD8 + CD8 + T cells 2.6 ± ± 0.6 CD3 + NK1.1 + NKT cells 3.0 ± ± 0.5 Bone marrow CD3 NK1.1 + NK cells 7.4 ± ± 3.1 CD19 + B cells 28.2 ± ± 9.8 CD11b + CD11c + DCs 7.4 ± ± 2.4 CD11b + CD11c Macrophages 41.2 ± ± 4.5 CD4 + CD8 + DP thymocytes 73.6 ± ± 2.0 Thymus SP CD4 + CD4 + CD8 thymocytes SP CD8 + CD4 CD8 + thymocytes 5.7 ± ± ± ± 0.5 a Results are presented as mean ± s.d. of 3 animals per group.